STAGE IIA FALLOPIAN TUBE CANCER AJCC V6 AND V7
Clinical trials for STAGE IIA FALLOPIAN TUBE CANCER AJCC V6 AND V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIA FALLOPIAN TUBE CANCER AJCC V6 AND V7 trials appear
Sign up with your email to follow new studies for STAGE IIA FALLOPIAN TUBE CANCER AJCC V6 AND V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare ovarian cancer: which chemo combo works best?
Disease control OngoingThis phase 3 trial tests two different chemotherapy regimens, with or without the targeted drug bevacizumab, as first treatment for a rare type of ovarian or fallopian tube cancer called mucinous epithelial cancer. About 50 patients with newly diagnosed or recurrent cancer will b…
Matched conditions: STAGE IIA FALLOPIAN TUBE CANCER AJCC V6 AND V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Weekly vs. Every-3-Weeks chemo: which works better for ovarian cancer?
Disease control OngoingThis phase III trial tested two different schedules of the chemotherapy drug paclitaxel (weekly vs. every three weeks) combined with carboplatin, with or without the targeted drug bevacizumab, in 692 patients with advanced ovarian, peritoneal, or fallopian tube cancer. The goal w…
Matched conditions: STAGE IIA FALLOPIAN TUBE CANCER AJCC V6 AND V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC